SAN DIEGO, Sept. 25, 2025 — ClearNote Health announced that it has received UK Conformity Assessed (UKCA) approval for its Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test, enabling commercialization in the United Kingdom. These approvals expand on a prior UKCA certification for the Avantect Pancreatic Cancer Test, strengthening the company’s portfolio of early detection diagnostics.
Science Significance
The Avantect tests use a liquid biopsy approach, analyzing epigenomic biomarkers (5-hydroxymethylcytosine, 5hmC) and genomic features in circulating cell-free DNA. This provides a highly specific signal of early cancer biology and can predict the tissue of tumor origin. By moving beyond traditional markers, these assays enable earlier detection of pancreatic, ovarian, and multiple other cancers when interventions are more effective.
Regulatory Significance
The UKCA marking confirms compliance with UK medical device regulations and is mandatory for diagnostic sales in the region. This regulatory milestone positions the Avantect platform for wider adoption in Europe’s post-Brexit market. The technology was also chosen as one of only two assays selected for the U.S. NIH’s Vanguard Study, underscoring its growing recognition by regulatory and scientific authorities.
Business Significance
Advertisement
Securing UKCA approval opens a major commercial market for the Avantect portfolio. With demand for multi-cancer early detection expanding, these approvals enhance the company’s ability to capture market share in precision oncology diagnostics. Participation in large-scale studies like the 24,000-participant Vanguard Study also bolsters credibility, making the technology more attractive for partnerships and healthcare adoption.
Patients’ Significance
For patients, these blood-based tests provide a noninvasive, highly sensitive tool for early cancer detection. The ovarian test, in particular, is designed for women at elevated genetic risk such as those carrying BRCA1/2 or Lynch syndrome mutations, offering earlier diagnoses that may improve survival outcomes. The multi-cancer test could benefit asymptomatic individuals, detecting malignancies that often go unnoticed until advanced stages.
Policy Significance
This approval highlights the role of regulatory frameworks like UKCA in accelerating access to life-saving diagnostics. As cancer remains a leading cause of mortality, policies encouraging adoption of multi-cancer early detection technologies will be critical for reducing healthcare burdens and supporting preventive care strategies.
The UK’s approval of the Avantect Multi-Cancer and Ovarian Cancer Tests represents a significant advance in precision diagnostics. By combining innovative epigenomic science, regulatory progress, and patient-focused design, these approvals reinforce the importance of next-generation cancer detection technologies in shaping the future of oncology care.
Source: ClearNote Health Press Release
